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Abstract
Introduction
Methadone has long been regarded as an effective treatment for opioid dependence. How-
ever, many patients discontinue maintenance therapy because of its side effects, with one
of the most common being sexual dysfunction. Buprenorphine is a proven alternative to
methadone. This study aimed to investigate sexual dysfunction in opioid-dependent men on
buprenorphine maintenance treatment (BMT) and methadone maintenance treatment
(MMT). The secondary aim was to investigate the correlation between sexual dysfunction
and the quality of life in these patients.
Methods
Two hundred thirty-eight men participated in this cross-sectional study. Four questionnaires
were used, the Mini International Neuropsychiatric Interview, Opiate Treatment Index,
Malay version of the International Index of Erectile Function 15 (Mal-IIEF-15), and World
Health Organization Quality of Life-BREF Scale. Multivariate analysis of covariance was
used to examine the relationship between MMT and BMT and the Mal-IIEF 15 scores while
controlling for all the possible confounders.
Results
The study population consisted of 171 patients (71.8%) on MMT and 67 (28.2%) on BMT.
Patients in the MMT group who had a sexual partner scored significantly lower in the sexual
desire domain (p < 0.012) and overall satisfaction (p = 0.043) domain compared with their
counterparts in the BMT group. Similarly, patients in the MMT group without a sexual part-
ner scored significantly lower in the orgasmic function domain (p = 0.008) compared with
those in the BMT group without a partner. Intercourse satisfaction (p = 0.026) and overall
satisfaction (p = 0.039) were significantly associated with the social relationships domain
after adjusting for significantly correlated sociodemographic variables.
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Conclusions
Sexual functioning is critical for improving the quality of life in patients in an opioid rehabilita-
tion program. Our study showed that buprenorphine causes less sexual dysfunction than
methadone. Thus, clinicians may consider the former when treating heroin dependents who
have concerns about sexual function.
Introduction
In 2005, the Malaysian government began the methadone maintenance treatment (MMT) pro-
gram as a national program, with 10,000 opioid-dependent individuals voluntarily enrolled [1].
Local data have shown that the MMT program has reduced crime rates and high-risk behavior
[2] and improved the quality of life [3], social functioning, and employment status [4] of heroin
dependents. Although the Malaysian government has strongly supported harm reduction poli-
cies, increasing the number of MMT programs remains an immense challenge. This may be
due to the methadone’s side effects, which may cause some patients to leave the MMT pro-
gram. One of the most common side effects of methadone is sexual dysfunction [5].
Numerous studies have been conducted on MMT, and many have found that sexual dys-
function, including hypoactive sexual desire disorder, erectile dysfunction, and orgasmic dys-
function, is common in heroin users and individuals being treated for heroin addiction [5–16].
In a recent meta-analysis, the meta-analytical pooled prevalence for sexual dysfunction among
methadone users was 52% (95% confidence interval, 0.39–0.65). Hypoactive sexual desire dis-
order and low libido were the most prevalent sexual dysfunctions, accounting for 51% of cases
[17]. Although reduction of the dose or discontinuation of methadone would be expected to
improve sexual function, conflicting results have been obtained in previous studies [5,7]. Other
possible confounders, such as depression, older age, psychological disorders, medical condi-
tions such as obesity and viral hepatitis, and unhealthy lifestyle [9,18–20], can have negative
effects on sexual function.
Methadone is a slow- and long-acting opiate agonist that stimulates μ-opioid receptors in
various areas of the brain. Several hypotheses have been suggested to explain the correlation
between methadone use and sexual dysfunction. One well-known hypothesis is that metha-
done exerts neuroendocrinological effects on the tubero-infundibular and hypothalamic-pitui-
tary-gonadal axes. The chronic stimulation of the μ-opioid receptors by methadone alters the
function of the tubero-infundibular axis and the dopaminergic control of prolactin, with a con-
sequential impact on sexual functioning [21]. A high level of circulating prolactin causes the
inhibition of the gonadotropin-releasing hormone, which lowers the levels of sex hormones,
especially testosterone. Men with low testosterone levels may exhibit a decrease in sexual inter-
est [22]. Furthermore, studies have also shown that methadone inhibits copulatory behavior
when administered acutely or chronically in animals, and it decreases socio-sexual interaction
without interfering with locomotion [23,24].
Buprenorphine, an alternative to methadone, has recently been increasingly recognized as
an effective anti-opioid addiction agent. It is a mixed agonist-antagonist opioid, with a low
intrinsic activity and a high affinity for the µ-opioid receptor and no intrinsic activity but a
high affinity for the κ-opioid receptor. Histological studies in buprenorphine-administered rats
showed no significant changes in the basement membrane, seminiferous tubules, Sertoli cells,
interstitial tissue, or sperm compared to a group that received methadone [25]. In humans,
however, the results have been contradictory. Some studies have found that, unlike MMT,
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buprenorphine maintenance treatment (BMT) was not associated with sexual dysfunction. In
contrast, other studies have found that erectile dysfunction was equally frequent in the two
groups [5,6,16,26]. All these trials, however, had small samples sizes; therefore, the role of
buprenorphine in sexual dysfunction in heroin-dependent patients is yet to be determined
[5,6].
A recent qualitative study [27] has found that some MMT subjects who experienced sexual
dysfunction chose to withdraw from interactions with their partners, which led to conflicts.
Such conflicts negatively impacted the rehabilitation. Furthermore, inappropriate reactions to
the sexual problems included premature treatment discontinuation under pressure from part-
ners, methadone dose reduction, and use of other illicit drugs to enhance sexual performance
[27]. Although sexual dysfunction is not life-threatening, it may often result in withdrawal
from sexual intimacy, thereby reducing quality of life [7].
Therefore, we conducted this study to investigate sexual dysfunction in opiate-dependent
men on MMT and BMT. We also investigated the correlation and association between sexual
dysfunction and quality of life in this group of patients.
Methods
This cross-sectional study included 238 men who received the MMT or BMT at the University
of Malaya Medical Center and University of Malaya Center of Addiction Sciences from Sep-
tember 2013 to September 2014. All patients who met the inclusion criteria were asked to parti-
cipate. Inclusion criteria were as follows: (a) age18 years, (b) presence of sexual activity (i.e.,
intercourse, caressing one’s partner without having intercourse, foreplay, and masturbation)
within the past 4 weeks, and (c) ability to understand and communicate in English or Bahasa
Malaysia to complete the study measurements. Exclusion criteria were as follows: (a) current
treatment with antiviral medication for viral hepatitis or HIV, androgen replacement therapy,
or phosphodiesterase type 5 inhibitors, (b) use of psychotropic medications other than metha-
done or buprenorphine, and (c) participation in MMT or BMT for<8 weeks. Written
informed consent was obtained from all study participants. Participation in the study was
voluntary and confidential, and no remuneration was provided. Both medications were admi-
nistered and prescribed to patients in the oral tablet form. The present study was conducted in
accordance with the Declaration of Helsinki, and the Medical Ethics Committee of University
Malaya Medical Center approved (902.17) and monitored the study.
All eligible participants agreed to complete an interview, which included questions on socio-
demographic factors such as duration of treatment and dosage of methadone or buprenor-
phine. The participants were assessed by using the Mini International Neuropsychiatric
Interview (M.I.N.I.) and Opiate Treatment Index (OTI). The participants also completed the
Malay version of the International Index of Erectile Function 15 (Mal-IIEF-15) andWorld
Health Organization Quality of Life-BREF Scale (WHOQOL-BREF) questionnaires.
Instruments
1. Mal-IIEF-15. The Mal-IIEF-15 is an easy-to-use, multi-dimensional self-reporting
instrument, which is available in multiple languages. It consists of 15 items that evaluate five
distinct domains of male sexual function over the preceding 4 weeks [28]. These domains and
the corresponding International Index of Erectile Function (IIEF) items explore erectile func-
tion (questions 1, 2, 3, 4, 5, and 15), orgasmic function (questions 9 and 10), sexual desire
(questions 11 and 12), intercourse satisfaction (questions 6, 7, and 8), and overall satisfaction
(questions 13 and 14). Each item is rated on a Likert scale ranging from 0 to 5, with a higher
score corresponding to better sexual function. The Malay version of the IIEF has been validated
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as a reliable instrument for measuring sexual dysfunction in the Malaysian male population. Its
Cronbach’s α value is at least 0.74, and the intra-class correlation coefficient is 0.59 [29]. In the
present study, a sexual partner was defined according to the IIEF-15 as a subject with whom
one has had sexual activity in the past 4 weeks.
2. M.I.N.I. The M.I.N.I. is a face-to-face, short, structured diagnostic interview designed
to identify 10 psychiatric disorders: mood disorders (major depression, bipolar disorder, dys-
thymia, and suicidality), panic disorder, social anxiety disorder, generalized anxiety disorders,
obsessive-compulsive disorder, post-traumatic stress disorder, psychotic disorders, substance
dependence and abuse, eating disorders, and antisocial personality [30]. The M.I.N.I. has good
validity and reliability, and it can be administered in 15–20 minutes [31]. In this study, this
instrument was used to rule out any comorbid psychiatric disorders in the patients on metha-
done maintenance.
3. OTI. The OTI is a multidimensional, structured, face-to-face interview used to evaluate
opiate treatment. The OTI consists of objective questions that assess six independent outcome
domains: drug use, HIV risk-taking behavior, social functioning, criminality, health status, and
psychological adjustment. All questions explore behavior in the month prior to the day of the
interview, except for the social functioning section, which covers the preceding 6 months. The
drug use domain is examined by collecting information on the last 3 days of drug use for each
drug category. For each drug class, the patient is asked to list their three most recent episodes
of drug use. A Q score is then calculated by adding the numbers of use episodes reported by the
subject and dividing the result by the total of two intervals between the reported use episodes.
A higher Q score corresponds to heavier drug use. In the other domains, all questions are
scored on a Likert scale ranging from 0 (best) to 5 (worst). The score for each domain is deter-
mined by adding the scores for each question. A higher score denotes a greater degree of dys-
function. The OTI typically takes 30 minutes to administer and is one of the evaluation tools
used by the MMT program [32].
4. WHOQOL-BREF. TheWHOQOL-BREF is an abbreviated version of the World Health
Organization Quality of Life-100 assessment. The questionnaire is used to assess an individual's
subjective perception of quality of life over the preceding 2 weeks. It consists of 26 questions
and primarily covers four domains (physical, psychological, social relationship, and environ-
ment). The total score of the WHOQOL-BREF ranges from 0 to 100, with higher scores reflect-
ing higher quality of life. The Malay version of the WHOQOL-BREF has been validated and
found to have sound psychometric properties (e.g., good discriminant and construct validities),
high internal consistency (0.64–0.80), and good test-retest reliability (0.49–0.88) [33]. This
scale was used to measure the quality of life in this group of patients.
Statistical Analysis
All analyses were conducted with the Statistical Package of Social Sciences, version 22.0 (SPSS,
Chicago, IL, USA). Descriptive statistics, including the mean, standard deviation, and fre-
quency, were computed for the baseline characteristics of the patients on MMT and BMT.
Demographic characteristics such as age, ethnicity, education level, employment status, marital
status, current methadone dose, history of hepatitis, and psychiatric comorbidities were com-
pared between the patients on methadone and buprenorphine. The groups were compared by
using the chi-square and Fisher exact tests for categorical variables, independent sample t-test
for normally distributed continuous variables, and Mann-Whitney U test for not normally dis-
tributed variables. Prior to analyzing continuous variables, normality was tested using the Sha-
piro-Wilk test. Analysis of covariance was performed using a general linear model (for
normally distributed variables) and a generalized linear model (for not normally distributed
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variables) to compare sexual function in patients on MMT and BMT using ethnicity, hepatitis
C status, education level, Q scores for tobacco and amphetamines, and social functioning deter-
mined by the OTI as covariates. A pairwise comparison was applied using a method based on
the Bonferroni test. We conducted a sub-analysis to further investigate those with and without
a sexual partner. Correlations between the Mal-IIEF-15 and WHOQOL-BREF domains were
evaluated for those with and without partners using partial correlation analysis with ethnicity,
hepatitis C status, education level, Q scores for tobacco and amphetamines, and social func-
tioning determined according to the OTI as covariates. The Fisher r-to-z transformation [34]
was also used to assess the significance of the difference between the WHOQOL-BREF and
Mal-IIEF-15 correlation coefficients in patients with partners on MMT and BMT. Hierarchical
multiple regression was then performed for the entire study population with partners using the
WHOQOL-BREF as the dependent variable and the Mal-IIEF-15 as the independent variable.
Prior to the regression analysis, the relationship between sociodemographic variables and
dependent variables was analyzed, and significantly correlated sociodemographic variables
were considered confounding variables in the analysis. All the significant confounding vari-
ables, excluding the sexual dysfunction components, were entered into the first block. The
independent variables were entered into the second block. Statistical significance was set at
p< 0.05 as determined using two-sided tests.
Results
In this study, 71.8% (n = 171) of the patients were on MMT, and the remaining 28.2% (n = 67)
were on BMT. The patients’ demographic and treatment details are shown in Table 1. Patients
on MMT and BMT differed in terms of ethnicity (p = 0.02); education level (p< 0.01); hepati-
tis C status (p< 0.01); and OTI Q scores for tobacco (p = 0.004), amphetamines (p = 0.037),
and social functioning (p< 0.01).
Multivariate analysis of covariance was used to compare the differences in the Mal-IIEF-15
scores between the MMT and BMT groups while controlling for ethnicity, education level,
hepatitis C status, Q scores for tobacco and amphetamines, and social functioning OTI
domains with pairwise comparisons using Bonferroni multiple testing corrections. Patients in
the MMT group, both with and without sexual partners, had lower Mal-IIEF-15 scores than
patients in the BMT group. Patients in the MMT group with sexual partners scored signifi-
cantly lower in the sexual desire (p< 0.012) and overall satisfaction (p = 0.043) domains than
patients in the BMT group (Table 2). Similarly, patients in the MMT group without a partner
scored significantly lower in the orgasmic function domain (p = 0.008) than patients without a
partner in the BMT group (Table 3). An analysis of marital status within the subgroup with
sexual partners did not reveal any differences (data not shown).
Table 4 shows the partial correlation coefficients between sexual function (Mal-IIEF-15)
and the WHOQOL-BREF scores in patients with sexual partners for MMT and BMT sepa-
rately. In the BMT group, intercourse function and erectile function were positively correlated
for all the WHOQOL-BREF domains. Sexual desire correlated significantly with only the psy-
chological (r = 0.444, p< 0.01) and social relationships (r = 0.500, p< 0.01) domains. In the
MMT group, overall satisfaction correlated strongly with the psychological (r = 0.309,
p< 0.01) and social relationships (r = 0.262, p< 0.01) domains in the WHOQOL-BREF.
The Fisher r-to-z transformation showed a relationship between psychological and sexual
desire (rMMT = 0.111, rBMT = 0.444, Z = 1.93, p = 0.026), and social relationships and sexual
desire (rMMT = 0.19, rBMT = 0.5, Z = 1.88, p = 0.03) were significantly different in the MMT and
BMT groups. Similarly, the relationships between intercourse and physical health (rMMT =
0.141, rBMT = 0.433, Z = 1.69, p = 0.04), and intercourse and social relationships (rMMT = 0.206,
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PLOS ONE | DOI:10.1371/journal.pone.0147852 January 28, 2016 5 / 12
Table 1. Demographic and Treatment Characteristics of All the Participants.
MMT (n = 171) BMT (n = 67) df χ2, Z,t p value
Age, years, mean ± SD 43.01 ± 9.52 43.43 ± 11.76 101.6 t = -0.261 0.79
Daily dose, mg, mean ± SD 77.08 ± 30.94 4.06 ± 2.78 — — N/A
BMI, kg/m2, mean ± SD 23.21 ± 4.85 22.33 ± 5.07 233 t = 1.226 0.23
Duration of MMT or BMT, months, mean ± SD 41.48 ± 28.60 50.03 ± 34.99 102.1 Z = -1.78 0.07
Current partner, n (%) 114 (66.7) 40 (59.7) 1 χ2 = 1.023 0.36
Marital Status, n (%)
Single 55 (32.2) 28 (41.8) 3 χ2 = 3.344 0.34
Married 100 (58.5) 36 (53.7)
Divorced 13 (7.6) 3 (4.5)
Ethnic Group, n (%)
Malay 144 (84.2) 46 (68.7) 3 χ2 = 9.475 0.02*
Chinese 15 (8.8) 14 (20.9)
Indian 10 (5.8) 7 (10.4)
Others 2 (1.2) 0
Religion, n (%)
Islam 144 (84) 48 (71.6) 4 χ2 = 6.284 0.18
Christianity 10 (5.8) 7 (10.4)
Buddhism 8 (4.7) 8 (11.9)
Hindu 6 (3.5) 3 (4.5)
Others 3 (1.8) 1 (1.5)
Education Level, n (%)
No education 2 (1.2) 0 3 χ2 = 17.386 <0.01**
Primary 11 (6.4) 17 (25.4)
Secondary 151 (88.3) 47 (70)
Tertiary 7 (4.1) 3 (4.5)
Employed, n (%) 143 (83.6) 60 (89.6) 1 χ2 = 1.348 0.24
Family history of drug use, n (%) 41 (24) 15 (22.4) 1 χ2 = 0.068 0.79
HBV+, n (%) 5 (2.9) 3 (4.5) 1 χ2 = 0.358 0.69
HCV+, n (%) 58 (33.9) 7 (10.4) 1 χ2 = 13.358 <0.01**
OTI Q scores for drug use domainϮ, mean ± SD
Tobacco 8.43 ± 6.28 6.50 ± 8.10 - Z = -2.867 0.004**
Alcohol 0.02 ± 0.12 0.14 ± 0.89 - Z = -0.731 0.465
Benzodiazepine 0.01 ± 0.07 0.07 ± 0.52 - Z = -1.605 0.108
Marijuana 0.03 ± 0.33 0.07 ± 0.56 - Z = -0.172 0.864
Amphetamines 0.003 ± 0.024 0.22 ± 1.71 - Z = -2.081 0.037*
Heroin 0.07 ± 0.43 0.13 ± 0.65 - Z = -0.06 0.947
Q scores for HIV risk-taking domain, mean ± SD 3.74 ± 3.47 3.05 ± 3.50 - Z = -1.511 0.13
Q scores for criminality domain, mean ± SD 0.04 ± 0.459 0 - Z = -0.626 0.531
Q scores for social functioning domain, mean ± SD 8.88 ± 5.08 6.72 ± 4.84 - Z = -3.127 0.002**
Q scores for health domain, mean ± SD 0.39 ± 1.13 0.40 ± 0.88 Z = -1.285 0.199
M.I.N.I. psychiatric disorders 48 (28.1) 19 (28.4) 5 χ2 = 8.713 0.711
MDD 16 (9.4) 7 (10.4)
ASD 29 (17) 11 (16.4)
Panic disorder 1 (0.6) 1 (1.5)
Dysthymia 1 (0.6) 0 (0)
Bipolar 1 (0.6) 0 (0)
ASD, antisocial disorder; BMI, body mass index; BMT, buprenorphine maintenance treatment; df, degrees of freedom; HBV, hepatitis B; HCV, hepatitis C;
Mal-IIEF-15, Malay version of the International Index of Erectile Function 15; HIV, human immunodeficiency virus; MDD, major depressive disorder; M.I.N.
I., Mini International Neuropsychiatric Interview; MMT, methadone maintenance treatment; OTI, Opioid Treatment Index; SD, standard deviation; t, t-test;
χ2, chi-square test; Z, z-test.
* p < 0.05
** p < 0.01
Ϯ Based on the Mann-Whitney test
doi:10.1371/journal.pone.0147852.t001
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rBMT = 0.590, Z = 2.17, p = 0.015) were also significantly different between the MMT and BMT
groups.
Table 5 shows that the overall satisfaction domain was significantly associated with the psy-
chology domain (p = 0.047) in the WHOQOL-BREF, whereas the intercourse satisfaction
(p = 0.026) and overall satisfaction (p = 0.039) domains were significantly associated with the
social relationships domain after adjusting for significantly correlated sociodemographic
variables.
Discussion
In our study, patients with sexual partners in the MMT group had lower scores for sexual
desire (p = 0.01) and overall satisfaction (p = 0.043) than patients with sexual partners in the
BMT group. Patients in the MMT group without a sexual partner also scored lower in orgasmic
function than their counterparts in the BMT group (p = 0.01). In addition, we found that the
sexual desire and intercourse domains positively correlated with the WHOQOL-BREF
domains, especially the social relationships domain, and these correlations were statistically
significant in the BMT group compared with the MMT group.
Table 2. Comparison of the Mean Mal-IIEF-15 Domain Scores in Patients with Sexual Partners in the MMT and BMTGroups.
Mal-IIEF-15 domain MMT (n = 114) mean ± SD BMT (n = 40) mean ± SD Mean differencea p valueb
Erectile function 21.77 ± 7.02 21.93 ± 8.48 -0.942 0.506
Orgasmic functionƚ 7.37 ± 2.86 7.40 ± 3.58 -0.07 0.902
Sexual desireƚ 6.31± 1.57 7.10 ± 1.58 -0.76 <0.012*
Intercourse satisfaction 8.81 ± 3.35 9.73 ± 4.38 -1.180 0.086
Overall satisfactionƚ 7.70 ± 1.92 8.35 ± 1.89 -0.73 0.043*
BMT, buprenorphine maintenance treatment; MMT, methadone maintenance treatment; Mal-IIEF-15, Malay version of the International Index of Erectile
Function 15; SD, standard deviation.
* p < 0.05
a Adjusted mean difference with ethnic group, education level, hepatitis C status, social functioning total score, and Q score for tobacco and
amphetamines as covariates.
b Adjusted for multiple comparisons using the Bonferroni correction.
ƚ A generalized linear model approach was used because the variables were not normally distributed.
doi:10.1371/journal.pone.0147852.t002
Table 3. Comparison of the Mean Mal-IIEF-15 Domain Scores of All Patients without a Sexual Partner in the MMT and BTMGroups.
Mal-IIEF-15 domain MMT (n = 57) mean ± SD BMT (n = 27) mean ± SD Mean differencea p valueb
Erectile function 8.37 ± 7.09 9.37 ± 8.29 -2.587 0.225
Orgasmic functionƚ 2.33 ± 3.23 3.85 ± 3.91 -2.47 0.008**
Sexual desire 5.91 ± 2.37 5.26 ± 1.91 0.51 0.373
Intercourse satisfactionƚ 1.44 ± 3.29 1.96 ± 3.94 -1.118 0.257
Overall satisfaction 4.39 ± 2.27 4.48 ± 2.47 -0.12 0.853
BMT, buprenorphine maintenance treatment; MMT, methadone maintenance treatment; Mal-IIEF-15, Malay version of the International Index of Erectile
Function 15; SD, standard deviation.
** p < 0.01
a Adjusted mean difference for the covariates (i.e., ethnic group, education level, hepatitis C status, social functioning total score, and Q score for tobacco
and amphetamines).
b Adjusted for multiple comparisons using the Bonferroni correction.
ƚ A generalized linear model approach was used because the variables were not normally distributed.
doi:10.1371/journal.pone.0147852.t003
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Patients with sexual partners in the BMT group had higher sexual desire than their counter-
parts in the MMT group after controlling for all possible confounders. This may indicate that
the loss of sexual desire caused by long-term methadone maintenance may be different from
that caused by long-term heroin abuse. Sexual desire is defined as the urge to engage in sexual
activity [35].Sexual activity is a natural reward in animals, including humans, and the expres-
sion of sexual behaviors is based on the influence of sexual excitatory and inhibitory mechan-
isms in the brain [36]. Although the excitatory mechanisms involve multiple
neurotransmitters, dopamine is the one that has been discussed for centuries [36]. The first
recognized dopamine-mediated enhancement of sexual behavior in humans occurred when it
was noticed that the administration of L-dopa (3,4-dihydroxy-l-phenylalanine), the precursor
of dopamine, to men suffering from Parkinson's disease resulted in increased libido and sexual
potency [37]. In contrast, endogenous opioid, endocannabinoid, and serotonin systems blunt
this excitatory mechanism and act as the sexual inhibitor to induce a restorative state of sexual
satiety that presents as a “refractory phase.” This endogenous inhibitory mechanism can also
be activated by situational variables such as stress or by drugs such as methadone, which is a
slow- and long-acting opioid agonist that works by stimulating μ-opioid receptors [37].
Table 4. Relationship between Sexual Dysfunction and Quality of Life for All Patients with a Sexual Partner in the MMT and BMTGroups a.
WHOQOL domain
Physical health Psychological Health Social relationships Environment
Mal-IIEF-15 domain MMT BMT MMT BMT MMT BMT MMT BMT
Erectile function 0.175 0.363* 0.222* 0.367* 0.162 0.367* 0.186 0.351*
Orgasmic function 0.161 0.268 0.211* 0.305 0.195* 0.278 0.215* 0.324
Sexual desire 0.075 0.086 0.111 0.444** 0.19 0.5** 0.112 0.283
Intercourse satisfaction 0.141 0.433** 0.277** 0.531** 0.206* 0.590** 0.207* 0.455**
Overall satisfaction 0.166 0.274 0.309** 0.241 0.262** 0.292 0.186 0.151
BMT, buprenorphine maintenance treatment; MMT, methadone maintenance treatment; Mal-IIEF-15, Malay version of the International Index of Erectile
Function 15; WHOQOL, World Health Organization Quality of Life.
* p < 0.05
**p < 0.01
a Adjusted for ethnic group, education level, hepatitis C status, social functioning total score, and Q scores for tobacco and amphetamines using the
partial correlation method.
doi:10.1371/journal.pone.0147852.t004
Table 5. Linear Regression Analysis of Sexual Dysfunction and Quality of Life for All Patients with a Sexual Partner in the MMT and BMTGroups.
Physical Health Psychological Health Social relationships Environment
Variable,n (%) B (β) p value B (β) p value B (β) p value B (β) p value
Erectile Function 0.017 (0.058) 0.71 -0.031 (-0.1) 0.531 -0.087 (-0.226) 0.139 -0.031 (-0.098) 0.55
Orgasmic Function 0.047 (0.067) 0.533 0.01 (0.013) 0.908 0.02 (0.021) 0.84 0.076 (0.098) 0.381
Sexual Desire -0.028 (-0.021) 0.813 0 (0) 0.997 0.257 (0.145) 0.099 0.05 (0.034) 0.721
Intercourse Satisfaction 0.033 (0.057) 0.723 0.185 (0.295) 0.074 0.272 (0.351) 0.026* 0.147 (0.226) 0.177
Overall Satisfaction 0.154 (0.14) 0.115 0.214 (0.18) 0.047* 0.264 (0.18) 0.039* 0.098 (0.08) 0.386
Adjusted R2 15.9% 11.1% 20.8% 8.2%
BMT, buprenorphine maintenance treatment; MMT, methadone maintenance treatment
* p < 0.05
doi:10.1371/journal.pone.0147852.t005
Sexual Dysfunction in Heroin Dependents
PLOS ONE | DOI:10.1371/journal.pone.0147852 January 28, 2016 8 / 12
Although normal sexual inhibition keeps individuals from engaging in risky or inappropriate
sexual behaviors, excessive central inhibition increases the risk of sexual dysfunction, including
inhibited arousal and desire and/or a diminished capacity to achieve sexual gratification [36].
Furthermore, there is some evidence that methadone interferes with the normal production of
hypothalamic and pituitary regulatory hormones that increase the serum prolactin level and
reduce the gonadotropin releasing hormone level, which indirectly suppresses testosterone
production [26]. Testosterone deficiency is accompanied by fatigue, weakness, mood distur-
bances, and decrease in libido and sexual function [38]. Therefore, the methadone’s effects on
sexual behavior are similar to those of anti-androgens [39]. Conversely, buprenorphine, which
is a partial opioid agonist of the μ receptor as well as the κ opioid receptor antagonist, induces
dopamine release and does not interfere with the sex hormones to the same extent as metha-
done, causing less reduction of sexual desire [40]. However, sexual desire is not solely depen-
dent on the biological component, and its psychological component is influenced by the
interpersonal state (presence or absence of sexual partner) and social context [41]. Accordingly,
we only observed changes in sexual desire in the patients who had sexual partners.
An orgasm is defined as a sudden discharge of accumulated sexual excitement during the
sexual response cycle causing rhythmic muscular contractions in the pelvic region that are
characterized by sexual pleasure. Medical professionals use physiological changes in the body
to define an orgasm, whereas psychologists and mental health professionals utilize emotional
and cognitive changes [42]. An orgasmic problem is a stressful condition that can prevent peo-
ple from having sexual and social relationships. In a study by Chekuri et al., nearly half of
patients without a sexual partner who were on MMT and suffered from an orgasmic problem
stated that they would be in a sexual relationship if they had no orgasmic problem [8]. This
may be the reason why the patients remained single and had no sexual partner. We also found
that men without a sexual partner who were on MMT had more orgasmic problems than men
without a sexual partner on BMT. This result is consistent with those of previous studies [43].
A recent study showed that problems with orgasm actually worsened after 6 months on MMT
[44]. The authors argued that this could be due to a variety of psychological and interpersonal
factors not monitored during MMT, and the causes remain unknown. Therefore, more
research should concentrate on orgasmic problems in this group of patients.
The second objective of our study was to investigate the correlation of sexual dysfunction
and quality of life in patients on MMT and BMT. We found that patients on BMT with a sexual
partner who had better sexual desire and intercourse scores on the IIEF15 reported a better
quality of life, especially in their social relationships. This agrees with the results of an Italian
longitudinal survey, in which 3105 (81.5%) MMT and 707 (18.5%) BMT subjects were assessed
for social life status based on percentage of subjects who were married or cohabiting. The study
found that the social life status was significantly better in the patients receiving BMT (63% and
39% of the BMT and MMT subjects, respectively, were married/cohabiting). The authors con-
cluded that improved psychosocial functioning in the BMT patients could contribute to better
reintegration into the community and to enhanced social activity [45]. In contrast, sexual dys-
function caused by MMT interferes with intimate relationships, which may reduce compliance
with the therapy and, consequently, its benefits. Patients who experience sexual dysfunction
may not have desire or confidence to maintain an intimate affective relationship with their
spouse or sexual partner, which in turn can cause tensions in the relationship. Such an attitude
may also result in their partners questioning the strength of the relationship, which may ulti-
mately lead to separation [27]. This was also observed in our study, as sexual satisfaction was
strongly associated with social relationships even after adjusting for all confounders. Therefore,
the problem of diminished sexual function in patients on MMT should be properly addressed.
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Several limitations of the present study need to be emphasized. First, presence of response
bias cannot be excluded because the topic of sex is considered private among more conservative
Malaysian patients, who may have concealed their true feelings because they felt too uncomfor-
table to reveal them to the researchers. Second, 238 participants constitute a relatively small
sample. Third, this cross-sectional study included men who received tertiary care in a hospital-
based opioid treatment program. Hence, the results cannot be generalized to all opioid users in
the community. Fourth, sexual hormonal assays such as assays for testosterone, free testoster-
one, prolactin, luteinizing hormone, and follicle-stimulating hormone were not performed in
this study owing to financial restrictions. However, previous studies have already shown that
patients on MMT have lower testosterone levels than patients on BMT [16,46], which may
explain the higher prevalence of sexual dysfunction in patients on MMT. Fifth, the nature of
the study design may have resulted in recall bias, possibly affecting the results. Sixth, we did
not consider duration of opiate dependence prior to treatment. Finally, the IIEF-15 is primarily
a validated instrument for measuring erectile dysfunction in men rather than orgasmic func-
tion or sexual desire.
In summary, sexual functioning is critical for improving the quality of life in patients in an
opioid rehabilitation program. Our study indicates that the use of buprenorphine is associated
with less sexual dysfunction than that of methadone in opioid-dependent patients. Hence, clin-
icians may consider the former agent when treating heroin dependents with concerns about
sexual function.
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